What are the risks of IV Rho immunoglobulin (RhIG) in the treatment of immune thrombocytopenic purpura (ITP) in children?

Updated: Jun 28, 2019
  • Author: Craig M Kessler, MD, MACP; Chief Editor: Srikanth Nagalla, MBBS, MS, FACP  more...
  • Print

The ASH notes the significant risk of hemolysis with IV RhoD immune globulin (RhIG, anti-D immune), and advises against its use in children with a hemoglobin concentration that is decreased because of bleeding, or in those with evidence of autoimmune hemolysis. However, the ASH suggests that a single dose of IV RhIG can be used as first-line treatment in Rh-positive, nonsplenectomized children with a negative direct antiglobulin test (DAT) who require treatment. [8]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!